Q-omics provides the consensus-scored ASF1B profile across patient tissues and cancer cell-line models. ASF1B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ASF1B is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ASF1B protein abundance shows 35,227 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where ASF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASF1B survival associations across molecular data types. ASF1B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASF1B RNA expression–survival associations across cancer types. High ASF1B expression shows unfavorable associations in KIRP, ACC, MESO, KICH, PAAD and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ASF1B RNA expression.
This table summarizes ASF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ASF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASF1B shows higher tumor expression in KIRC, HNSC, BLCA, KIRP, LUAD and THCA. The KIRC box plot shows higher ASF1B RNA expression in tumor versus normal tissue (log2 FC = +2.011, t-test p < 0.001).
This table shows molecular features associated with ASF1B in patient tissues and cancer cell lines. In patient samples, ASF1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
